Elif Birtas Atesoglu on Muck Rack

Elif Birtas Atesoglu

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Elif Birtas

Contact Elif Birtas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Exploring an independent association between rituximab‐cyclophosphamide‐doxorubicin‐vincristine‐prednisolone dose intensity and clinical outcomes in large B‐cell lymphoma: Analyses of subsequent endpoints following a complete response in a real‐world coho

|
By Umut Yılmaz, Mehmet Sinan Dal, Turgay Ulas, Elif Birtas Atesoglu
| Wiley Online Library Verified
CONFLICT OF INTEREST STATEMENT No conflicts of interest declared. DATA AVAILABILITY STATEMENT The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available because of privacy or ethical restrictions. Supporting Information Filename Description cncr70248-sup-0001-suppl-data.pdf654.4 KB Supplementary Material REFERENCES 1, , , et al.
Open in Who Shared Issue with article?

Glofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world data

|
By Zafer Gülbas, Muhit Ozcan, Elif Birtas Atesoglu, Ant Uzay
| Wiley Online Library Verified
Abstract Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion trial conducted in patients with relapsed/refractory (R/R) B-cell lymphoma. However, the real-world data of patients of all ages with no strict selection criteria are still lacking.
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified